γ-phenylitaconic anhydride | 142210-40-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: γ-phenylitaconic anhydride
• 英文别名: phenylation-oic acid anhydride；Phenylaticon-saeureanhydrid；Benzylidenesuccinic Anhydride；2-phenylmethylenesuccinic anhydride；(Z)-benzylidenesuccinic anhydride；(3Z)-3-benzylideneoxolane-2,5-dione
• CAS: 142210-40-0
• 化学式: C₁₁H₈O₃
• 分子量: 188.183
• InChiKey: WHRPHGQMEZWMNF-TWGQIWQCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  γ-phenylitaconic anhydride 在 一水合肼 作用下， 反应 4.0h， 生成 bis (γ-phenylitaconamic acid)
  参考文献：
  名称：

  Wahhab, Samiha M. Abdel; Abdallah, Shadia M.; Elmaria, Fatma A., Revue Roumaine de Chimie, 2003, vol. 48, # 8, p. 619 - 627

  摘要：

  DOI：
• 作为产物：
  描述：

  (E)-乙苯亚甲基丁二酸 以 Ac2 O 为溶剂， 生成 γ-phenylitaconic anhydride
  参考文献：
  名称：

  Hydroxyazido derivatives and related compounds as renin inhibitors

  摘要：

  提供了作为肾素抑制剂有用的新型化合物。这些化合物是具有结构式##STR1##的羟基叠氮衍生物，其中取代基R.sub.1到R.sub.7如本文中所定义。此外还提供了这些化合物的酮叠氮衍生物的类似物。此外还披露了使用这些新型化合物治疗高血压的方法以及含有这些化合物的药物组合物。特别感兴趣的是口服给药的配方。

  公开号：

  US05268361A1

文献信息

• Hydroxyazido derivatives and related compounds as renin inhibitors
  申请人：SRI International

  公开号：US05268361A1

  公开（公告）日：1993-12-07

  Novel compounds useful as renin inhibitors are provided. The compounds are hydroxyazido derivatives having the structural formula ##STR1## wherein the substituents R.sub.1 through R.sub.7 are as defined herein. Analogs of these compounds which are ketozaido derivatives are also provided. Additionally disclosed re methods for using the novel compounds to treat hypertension, and pharmaceutical compositions containing the compounds. Of particular interest are formulations for oral administration.

  提供了作为肾素抑制剂有用的新型化合物。这些化合物是具有结构式##STR1##的羟基叠氮衍生物，其中取代基R.sub.1到R.sub.7如本文中所定义。此外还提供了这些化合物的酮叠氮衍生物的类似物。此外还披露了使用这些新型化合物治疗高血压的方法以及含有这些化合物的药物组合物。特别感兴趣的是口服给药的配方。
• Succinic acid compounds
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US05202335A1

  公开（公告）日：1993-04-13

  Succinic acid compounds of the formula: ##STR1## wherein A represents a heterocyclic group, a 3 to 8-membered cycloalkyl group or a phenyl group which may have one or more substituents selected from the group of a halogen atom, a lower alkyl group having 1 to 6 carbon atoms and a lower alkoxy group having 1 to 6 carbon atoms; B represents a bicyclic amino group which may have 1 or 2 unsaturated bonds, with the proviso that B bonds to the carbon atom of the carbonyl group at the nitrogen atom; R represents a hydrogen atom or combines each other to form a chemical bond; R.sup.1 represents a hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms or an aralkyl group having 7 to 10 carbon atoms; when there is an asymmetric carbon atom, enantiomers thereof and racemic mixtures thereof; when there are geometrical isomers, each geometrical isomer, E-isomers thereof, Z-isomers thereof, cis-isomers thereof and trans-isomers thereof; and pharmaceutically acceptable salts thereof, enhance insulin secretion and possess a hypoglycemic activity, and are thus useful for the treatment of diabetes.

  Succinic acid compounds of the formula: ##STR1## wherein A represents a heterocyclic group, a 3 to 8-membered cycloalkyl group or a phenyl group which may have one or more substituents selected from the group of a halogen atom, a lower alkyl group having 1 to 6 carbon atoms and a lower alkoxy group having 1 to 6 carbon atoms; B represents a bicyclic amino group which may have 1 or 2 unsaturated bonds, with the proviso that B bonds to the carbon atom of the carbonyl group at the nitrogen atom; R represents a hydrogen atom or combines each other to form a chemical bond; R.sup.1 represents a hydrogen atom, a lower alkyl group having 1 to 6 carbon atoms or an aralkyl group having 7 to 10 carbon atoms; when there is an asymmetric carbon atom, enantiomers thereof and racemic mixtures thereof; when there are geometrical isomers, each geometrical isomer, E-isomers thereof, Z-isomers thereof, cis-isomers thereof and trans-isomers thereof; and pharmaceutically acceptable salts thereof, enhance insulin secretion and possess a hypoglycemic activity, and are thus useful for the treatment of diabetes.
• Contrast enhanced photolithography
  申请人：GEC-MARCONI LIMITED

  公开号：EP0239376A2

  公开（公告）日：1987-09-30

  The contrast and sharpness of photoresist images is enhanced by depositing a layer of a photobleachable compound onto the photoresist layer. The photobleachable layer is sensitive to the light used to expose the photoresist and forms a contrast enhancement layer (CEL) on the photoresist layer. Fulgides and photochromic butyrolactones are selected for forming the photobleachable layer. Such compounds can be deposited from a hydrocarbon solution, such as toluene, and are soluble in the standard alkali, photoresist developers. The process is particularly advantageous for producing integrated circuits.

  通过在光刻胶层上沉积一层可光漂白化合物，可增强光刻胶图像的对比度和清晰度。 可光漂白层对用于曝光光刻胶的光敏感，并在光刻胶层上形成对比度增强层（CEL）。 可光漂白层的形成可选用呋喃类化合物和光致变色丁内酯。 这类化合物可从甲苯等烃溶液中沉积，并可溶于标准的碱和光刻胶显影剂。 该工艺尤其适用于生产集成电路。
• Verfahren zur enantioselektiven Synthese von 2(R)-Benzylbernsteinsäuremonoamid-Derivaten
  申请人：HOECHST AKTIENGESELLSCHAFT

  公开号：EP0512415A2

  公开（公告）日：1992-11-11

  Es werden zwei Verfahren zur Herstellung der optisch reinen Verbindungen der allgemeinen Formel 1 beschrieben. wobei R1, R2 z. B. gleich Alkyl, R3, R4 z. B. gleich Wasserstoff und R5 z. B. gleich Wasserstoff bedeuten. Beide Verfahren beinhalten als Schlüsselschritte die enantioselektive Hydrierung einer C = C-Doppelbindung und die regioselektive Monoamidbildung eines Dicarbonsäurederivats.

  本文介绍了制备通式 1 光学纯化合物的两种工艺。 其中 R1、R2 例如是烷基、 R3、R4 例如为氢，以及 R5 例如为氢。 这两种工艺的关键步骤是 C = C 双键的对映选择性氢化和二羧酸衍生物的区域选择性单酰胺形成。
• HYDROXYAZIDO DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS
  申请人：SRI INTERNATIONAL

  公开号：EP0587767A1

  公开（公告）日：1994-03-23